Grant: Master's Award: Canada Graduate Scholarships
University of Toronto
$17,500.00
Prescribing characteristics associated with sustained abstinence following buprenorphine treatment in adults with opioid use disorder
FY 2019-20
Summary
"Buprenorphine/naloxone (buprenorphine) is an effective and preferred treatment for opioid addiction due to its favourable safety profile and ease of use. Use of this medication has been associated with a number of benefits for individuals and society, including reduced risk of death, lower risk of viral infections, and reduced crime. Despite these benefits, a substantial proportion of patients using this medication ask to stop taking it. Some reasons for discontinuation include cost, having to attend medical appointments, and not wanting to be 'dependent' on a stigmatized medication. Unfortunately, discontinuing buprenorphine is associated with an increased risk of relapse to street opioids and subsequent overdose death. Furthermore, physicians have limited evidence to guide how to taper people off this medication safely. In this study, we propose to use administrative health data from Ontario to understand what prescribing characteristics (such as rate of taper, duration of treatment prior to taper, duration of taper, etc.) are associated with sustained abstinence. Sustained abstinence is defined as no return to treatment, no opioid-related hospitalizations, and no death for 18 months after stopping the medication. Given that buprenorphine is now the preferred option for the treatment of opioid addiction, and considering the substantial risks related to relapse, identifying taper characteristics associated with sustained abstinence is an important clinical and patient-centred question and could contribute significantly to reduction in opioid-related overdose-death. "
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
428716
Name
Bozinoff Nikki
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Prescribing characteristics associated with sustained abstinence following buprenorphine treatment in adults with opioid use disorder
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Addiction; Buprenorphine; Mental Health; Opioid Use Disorder; Opioids; Treatment
Abstract
"Buprenorphine/naloxone (buprenorphine) is an effective and preferred treatment for opioid addiction due to its favourable safety profile and ease of use. Use of this medication has been associated with a number of benefits for individuals and society, including reduced risk of death, lower risk of viral infections, and reduced crime. Despite these benefits, a substantial proportion of patients using this medication ask to stop taking it. Some reasons for discontinuation include cost, having to attend medical appointments, and not wanting to be 'dependent' on a stigmatized medication. Unfortunately, discontinuing buprenorphine is associated with an increased risk of relapse to street opioids and subsequent overdose death. Furthermore, physicians have limited evidence to guide how to taper people off this medication safely. In this study, we propose to use administrative health data from Ontario to understand what prescribing characteristics (such as rate of taper, duration of treatment prior to taper, duration of taper, etc.) are associated with sustained abstinence. Sustained abstinence is defined as no return to treatment, no opioid-related hospitalizations, and no death for 18 months after stopping the medication. Given that buprenorphine is now the preferred option for the treatment of opioid addiction, and considering the substantial risks related to relapse, identifying taper characteristics associated with sustained abstinence is an important clinical and patient-centred question and could contribute significantly to reduction in opioid-related overdose-death. "
Competitiondate
201912
Approvedterm2
1 yr 0 mth
Pinamesdelim
Bozinoff, Nikki
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~